ARUP's studies also indicate elevated serum CgA levels in the advanced stages of other non-endocrine carcinomas. The determination of serum CgA levels can therefore have implications in the type of therapy used for treatment. The major use of serum CgA is as a tumor marker for neuroendocrine tumors. The assay provides a means of determining serum CgA levels for aiding in the diagnosis and prognosis of such diseases, and for the monitoring of patients' response to therapy. Assay results in and of themselves are not diagnostic and CgA should not be considered a screening test for neuroendocrine tumors .
Results are to be interpreted in conjunction with other laboratory tests.
As with other secreted proteins, serum CgA may be elevated in patients experiencing renal failure due to its retention in the serum. This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test should not be regarded as investigational or for research use. Deftos LJ, et al.